

Received: 2020.04.29

Accepted: 2020.07.11

Available online: 2020.07.21

Published: 2020.09.14

# A Systematic Pharmacology and *In Vitro* Study to Identify the Role of the Active Compounds of *Achyranthes bidentata* in the Treatment of Osteoarthritis

Authors' Contribution:

Study Design A

Data Collection B

Statistical Analysis C

Data Interpretation D

Manuscript Preparation E

Literature Search F

Funds Collection G

ABCDE 1,2

AG 1,3

E 1

**Zhenyuan Chen**

**Guangwen Wu**

**Ruoxi Zheng**

1 Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, P.R. China

2 Department of Clinical Medicine, Fujian Health College, Fuzhou, Fujian, P.R. China

3 Fujian Provincial Key Laboratory of Integrative Medicine on Geriatrics, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, P.R. China

**Corresponding Author:**

Guangwen Wu, e-mail: [wuguangwenfj@163.com](mailto:wuguangwenfj@163.com)

**Source of support:**

This study was supported by the National Natural Science Foundation of China (grant no. 81774345), the Natural Science Foundation of Fujian Province (grant no. 2018J01874), the Developmental Fund of Chen Keji Integrative Medicine (grant no. CKJ2020005), and the 2017 Science and Technology project of Traditional Chinese Medicine of Fujian Province (grant no. 2017FJZYJC204)

**Backgrounds:**

*Achyranthes bidentata* is a Chinese traditional herbal medicine widely used to treat osteoarthritis (OA). This study aimed to identify active compounds from *Achyranthes bidentata* through systematic pharmacology and *in vitro* experiments to find the targets of *Achyranthes bidentata* in the treatment of OA.

**Material/Methods:**

We screened the active compounds of *Achyranthes bidentata* from the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database. Then, we used STITCH and Open Targets Platform databases to screen the active components and predict the potential targets of *Achyranthes bidentata* in the treatment of OA. Subsequently, we studied the compound-target network and protein interaction network and analyzed the enrichment of potential target proteins. Finally, we used Western blot analysis to verify the therapeutic effect of *Achyranthes bidentata* extract on the expression of OA-related target proteins.

**Results:**

There were 7 active components in *Achyranthes bidentata*, which were strongly related to the 74 targets of OA. Quercetin, baicalein, and berberine are the critical active compounds of *Achyranthes bidentata* in the treatment of OA. Protein interaction analysis and *in vitro* experiments suggested that TNF, IL-6, and TP53 are the critical targets of *Achyranthes bidentata* in the treatment of OA. Functional enrichment analysis showed that *Achyranthes bidentata* plays a pharmacological role in OA through apoptosis, inflammation, and immune regulation.

**Conclusions:**


Quercetin, baicalein, and berberine are the critical active compounds of *Achyranthes bidentata* in the treatment of OA. TNF, IL-6, and TP53 may be potential targets for the treatment of OA.

**MeSH Keywords:**

**Medicine, Chinese Traditional • Molecular Mechanisms of Pharmacological Action • Osteoarthritis • Computer Communication Networks • Achyranthes**

**Full-text PDF:**

<https://www.medscimonit.com/abstract/index/idArt/925545>

 2546

 1

 5

 44



## Background

Osteoarthritis is a chronic degenerative and disabling arthropathy of complex etiology. Its main clinical manifestations are joint pain and deformity and movement limitation [1]. Most scholars believe that it is the result of an imbalance between degradation and synthesis among articular cartilage cells, extracellular matrix, and sub-cartilage bone [2]. At present, the leading role of drugs in the treatment of osteoarthritis is to relieve symptoms, but they cannot effectively prevent the development of osteoarthritis [3]. Therefore, it is of considerable significance to find a safe and effective drug for treating OA.

*Achyranthes bidentata* is a natural plant-derived traditional Chinese medicine (TCM), which is called ‘NIU XI’ in China. *Achyranthes bidentata* has long been used in TCM to treat “rheumatism arthralgia syndrome” by removing blood stasis and relieving pain, and it is a TCM commonly used in the treatment of osteoarthritis [4,5]. Recent pharmacological studies have demonstrated that *Achyranthes bidentata* can protect cartilage by reducing inflammation and apoptosis and by promoting cartilage proliferation [6,7]. However, the chemical composition of *Achyranthes bidentata* is complex, and the mechanism by which it affects osteoarthritis at the molecular level is unclear.

Systematic pharmacology applies the knowledge of system biology to pharmacology. The purpose of this discipline is to clarify how drugs act on the body through biological systems. Unlike evaluating the effect of a drug by a particular protein–drug reaction, systematic pharmacology suggests that drugs act by forming a network of interactions [8]. Interaction systems may include drug–protein and protein–protein interactions, as well as genetic, signaling, and physiological interactions. Systematic pharmacology uses bioinformatics and statistics to integrate and explain the network of drug interactions, which provides an effective method to study the biological mechanisms of TCM in treating diseases [9,10].

A recent systematic pharmacological study of *Achyranthes bidentata* suggested that PIM1, CYP1B1, and HSPA2 are critical targets in the treatment of OA using *Achyranthes bidentata*, but this has not been verified [11]. In the present study, we combined systematic pharmacology and *in vitro* experiments to screen the active components of *Achyranthes bidentata* in treating OA, to predict and verify its targets, and to provide a theoretical basis for the clinical application of drugs. The study flowchart is presented in Figure 1.

## Material and Methods

### Screening for active compounds

The Traditional Chinese Medicine Systems Pharmacology database (TCMSP; <http://tcmsp.com/tcmsp.php>) is a systematic pharmacological database for evaluating the pharmacokinetic properties of traditional Chinese medicine or related compounds [12]. It provides data on the absorption, distribution, metabolism, and excretion (ADME) of traditional Chinese herbs *in vivo*, including oral bioavailability (OB) and drug-like (DL). OB is the most critical index used to evaluate the effectiveness of oral drugs [13]. DL refers to the similarity between components and known drugs. In drug development, DL evaluation helps to identify qualified compounds and improve the success rate of candidate drugs [14]. Based on the published literature and preliminary information in the TCMSP database [15], we entered the drug name “*Achyranthes bidentata*” into the search box in the TCMSP database and screened the ingredients with OB  $\geq 30\%$  and DL  $\geq 18\%$  for further study.

### Identification of drug targets

The STITCH (<http://stitch.embl.de/>) database was used to search the potential target proteins of active components in *Achyranthes bidentata* [16]. STITCH is a database used to explore and predict the interaction between compounds and proteins. Through experiments, databases, and evidence in the literature, chemicals are shown to be associated with other chemicals and proteins. In the present study, we input active components into the STITCH database to screen *Achyranthes bidentata* target proteins with confidence  $> 0.4$  in the human species for further analysis.

### Identification of disease targets

OA targets were collected from the Open Targets Platform (<https://www.targetvalidation.org>) [17], which is a comprehensive and authoritative database for screening and visualizing potential drug targets related to diseases. It brings together a variety of data types designed to help users identify and prioritize targets for further research [18]. We used the keyword “osteoarthritis” in the Open Targets Platform. Then, the proteins overlapping the *Achyranthes bidentata* targets were selected for further study.

### Construction of a component–target network

A ‘component–target network’ diagram was constructed using Cytoscape 3.7.1 (<https://cytoscape.org/>) software to reveal the main active components and regulatory mechanisms of *Achyranthes bidentata* in the treatment of OA [19].




Figure 1. Study flow chart.

### Construction of a target–target interaction network

A target–target interaction network based on STRING11.0 (<http://string-db.org/>) was constructed in Cytoscape3.7.1 to identify the critical proteins among the target proteins listed above [20].

### Analysis of gene function and signal pathway enrichment

ClusterProfiler was used to analyze the enrichment of biological processes and signaling pathways. ClusterProfiler is an R package for gene cluster enrichment analysis, which can be used to thoroughly understand the function of genes and the enrichment of pathways [21]. Given the overlapping target gene list, clusterProfiler will use the Gene Ontology (GO) and

the Kyoto Encyclopedia of Genes and Genomes (KEGG) databases to analyze the biological process and signal pathway enrichment of the given gene list [22–24].

### **In vitro verification**

#### **Animals**

We purchased a total of 6 Sprague Dawley (SD) rats (4 weeks old, weight 95–110 g, both sexes) from Shanghai SLAC Laboratory Animal, Inc., China [Laboratory Animal Use Certificate no. SCXK(SH)2017-0005] and raised them in a sterile environment. Experiments involving animals complied with the 2006 edition of the guidelines for the Care and Use of Experimental Animals by the Ministry of Science and Technology, China [2]5.

#### **Preparation of *Achyranthes bidentata* extract**

*Achyranthes bidentata* was purchased from Guo Yi Tang Pharmaceutical in Fujian Province, China. Dr. Xu Wen, Department of Pharmacology, Fujian University of Traditional Chinese Medicine, identified the original herbs as *Achyranthes bidentata*. Then, *Achyranthes bidentata* (500 g) was crushed into a fine powder and boiled twice with 4 L of 80% ethanol for 1 hour. We collected the ethanol extract and filtered it. The filtrate was concentrated to 500 mL at 50°C under decompression, and the concentration was 2 g/mL.

#### **Chondrocytes culture and identification**

Briefly, the rats were anesthetized by intraperitoneal injection of 2% pentobarbital and then sacrificed via rapid decapitation. Then, cartilage tissue of rats was taken under aseptic conditions. The cartilage tissue was cut into pieces and digested with 0.5% type II collagenase (Sigma, Darmstadt, Germany) at 37°C for 5 hours. We filtered the cells with a 70-µm cell filter and washed them 3 times with aseptic phosphate-buffered saline (PBS; HyClone, Logan, UT, USA). After that, the collected cells were inoculated into a cell culture flask containing Dulbecco's modified Eagle's medium (DMEM; HyClone, Logan, UT, USA) with 10% fetal bovine serum (Gibco, New York, USA) and cultured at 37°C and 5% CO<sub>2</sub>. We changed the culture medium every 48 hours. We identified primary chondrocytes by type II collagen immunofluorescence staining using a previously described method [26,27]. Only primary or second-generation chondrocytes were used for the experiment.

#### **Establishment of a degenerative chondrocyte model**

We used IL-1β to establish a model of degenerative chondrocytes using methods described elsewhere [28,29]. Briefly, we treated secondary chondrocytes with 10 ng/ml IL-1β for 24 hours.

### **Experimental grouping**

We divided the cells into 2 groups: i) the degenerative chondrocyte group and ii) the degenerative chondrocyte with *Achyranthes bidentata* extract group. The intervention time for each group was 24 hours. We treated the chondrocytes with the *Achyranthes bidentata* extract, as described previously [30].

### **Western blot analysis**

The expression level of the target protein in chondrocytes of each group was calculated by Western blot and semi-quantitative analysis, using methods we described previously [31]. The following antibodies were used: TNF-α antibody (1: 1000; Abcam, Cambridge, MA, USA), IL-6 antibody (1: 1000; Abcam, Cambridge, MA, USA), p53 antibody (1: 1000; Cell Signaling Technology, Inc., Danvers, MA, USA), β-actin antibody (1: 2000; Abcam, Cambridge, MA, USA), and secondary antibodies (1: 20 000; Merck Millipore, Darmstadt, Germany).

## **Results**

### **Screening results of components and potential targets for *Achyranthes bidentata***

As described in the Methods section above, we searched the TCMSp database with the keyword "*Achyranthes bidentata*" for 176 herbal ingredients. According to the threshold described in the Methods section, 20 herbal ingredients were obtained.

We searched the STITCH database for 20 compounds screened from the TCMSp database, of which 7 compounds had 131 target proteins. Among them, *baicalin* has 37 targets, *β-sitosterol* has 11 targets, *kaempferol* has 18 targets, *quercetin* has 46 targets, *stigmaterol* has 3 targets, *baicalin* has 11 targets, and *berberine* has 49 targets. Table 1 shows the ADME properties of these 7 compounds.

### **Identification of osteoarthritis-related proteins**

By searching the Open Targets Platform database, we identified 74 targets closely related to OA as potential targets for the treatment of OA (Figure 2A). Then, we established a network of compounds–targets (Figure 2B). Among these 7 compounds, *quercetin* (Degree=28), *berberine* (Degree=25), and *baicalein* (Degree=26) connect more targets than the other 4 compounds, which suggests that they play an essential role in OA. All active ingredients of *Achyranthes bidentata* are linked to more than 2 targets, which indicates that *Achyranthes bidentata* showed multi-targeting in the treatment of OA.

**Table 1.** The absorption, distribution, metabolism, and excretion (ADME) properties of 7 active compounds from *Achyranthes bidentata*.

Mol ID	Molecule name	OB (%)	DL
MOL001454	Berberine	36.86	0.78
MOL000173	Wogonin	30.68	0.23
MOL002714	Baicalein	33.52	0.21
MOL00035	β-sitosterol	36.91	0.75
MOL000422	Kaempferol	41.88	0.24
MOL000449	Stigmasterol	43.83	0.76
MOL000098	Quercetin	46.43	0.28

### Target–target interaction analysis

By using Cytoscape 3.7.1, we constructed a diagram of the “target–target network” based on the results from the STRING database (Figure 3A). We constructed a bar plot according to the degrees of connection between the targets (Figure 3B). The results show that IL-6, TNF, and TP53 are the central targets in the network and connect to the most targets.

### Gene function and signal pathway enrichment analysis


GO and KEGG analyses were performed with clusterProfiler to analyze the functional characteristics of the targets, and

the threshold was set as  $P \leq 0.01$ . The results of GO analysis showed that 317 GO terms were enriched in ‘Biological Process’ (BP). The first 20 items with the most significant P-values are shown in Figure 4A. As presented, response to lipopolysaccharide, response to oxidative stress, response to a steroid hormone, and regulation of inflammatory response are involved in supporting the role of *Achyranthes bidentata* in treating OA.

The results of KEGG pathway enrichment showed that there are 34 signal pathways. The first 20 signaling pathways with the most significant P-values are shown in Figure 4B. As presented, Apoptosis, TNF signal pathway, T cell receptor signal pathway, Toll-like receptor signal pathway, Osteoclast differentiation, NF-κB signal pathway, and MAPK signal pathway are involved in supporting the effect of *Achyranthes bidentata* in treating OA.


### Western blot analysis

The protein expressions of TNF-α, IL-6, and p53 were calculated to verify the effect of *Achyranthes bidentata* on OA, as shown in Figure 5A–5D. Compared with the degenerative chondrocyte group, the *Achyranthes bidentata* group had lower expressions of TNF-α ( $P < 0.05$ ), IL-6 ( $P < 0.01$ ), and p53 ( $P < 0.05$ ) proteins.



**Figure 2.** Venn analysis and network analysis of active compounds and potential targets of *Achyranthes bidentata* on OA. (A) The Venn diagram of target proteins of *Achyranthes bidentata* and OA-related targets based on the Open Targets Platform. (B) The compound–targets network diagram of *Achyranthes bidentata* to treat OA, the square nodes represent compounds. The circular nodes represent target proteins.





**Figure 3.** ‘Target–Target’ interaction network analysis. (A) The target–target interaction network is constructed by using Cytoscape 3.7.1. The size of the nodes is proportional to degrees. (B) The bar plot on degrees of connection among the targets.


### Discussion

The systematic pharmacology method was developed for use with the molecular biological network analysis, which is used to discover new therapeutic drugs derived from natural products. Therefore, it provides a systematic means to expand the application of available drug compounds in TCM to treat a variety of complex diseases. OA is a common type of chronic arthritis with painful symptoms that affect patient quality of life. Although *Achyranthes bidentata* is an effective Chinese traditional herbal medicine used in the treatment of OA for several centuries, the molecular mechanism underlying its effects have been unclear.

In this study, we evaluated the active components and target proteins of *Achyranthes bidentata* in treatment of OA using systematic pharmacology, including ADME system evaluation, drug targeting, mechanism and pathway research, and molecular docking. Seven active components were screened and interacted with 73 different targets related to OA. According to the analysis of the “component–target network” model, *quercetin* showed the most target connections (Degree=28), followed by *baicalein* (Degree=26) and *berberine* (Degree=25). *Quercetin* is one of the most abundant flavonoids in plants and is well known for its antioxidant [32] and anti-inflammatory activities [33]. It plays an active role in anti-OA by promoting the apoptosis of fibroblasts-like synoviocytes in arthritis and protecting cartilage cells from oxidative stress [34,35]. *Baicalein* is a natural compound with potent antioxidant and anti-inflammatory activities [35,36]. Studies have shown that *baicalein*

reduces the pro-inflammatory mediators in human OA chondrocytes stimulated by inhibiting the NF-κB pathway [35,37]. *Berberine* has a wide range of biological functions *in vivo*, including antioxidant, anti-inflammatory, hypolipidemic, and hypoglycemic effects [38]. A previous study showed that *berberine* can inhibit the inflammatory response in rat articular cartilage cells [39]. Combined with the results of this study, the evidence suggests that *quercetin*, *baicalein*, and *berberine* are 3 critical active components of *Achyranthes bidentata* in the treatment of OA. A previous systematic pharmacological study of *Achyranthes bidentata* showed that *quercetin* is the main active component of *Achyranthes bidentata* in the treatment of OA [11], which agrees with our results. Moreover, as presented in the ‘component–target’ network analysis, *baicalein* and *berberine* also appear to play essential roles in OA.

TNF-α and IL-6 are 2 essential targets of OA anti-inflammatory therapy and are central inflammatory cytokines involved in articular cartilage degradation. TNF-α has a variety of biological effects that can directly cause peroxidation of chondrocytes and promote degradation of the cartilage matrix. It can also induce the release of other inflammatory cytokines such as IL-1 and IL-6 by activating the NF-κB pathway and MAPK pathway [40]. IL-6 has a synergistic effect with TNF in the pathogenesis of OA and can induce osteoclast differentiation and accelerate the destruction of articular cartilage [41]. In this study, TNF and IL-6 were the found to be critical elements of the protein interaction network, and Western blot analysis confirmed that *Achyranthes bidentata* extract can inhibit the expression of TNF-α and IL-6 in rat articular degenerative chondrocytes




**Figure 4.** The bar plot of Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. **(A)** The first 20 biological processes of GO analysis. **(B)** The first 20 signal pathways of KEGG enrichment analysis.

*in vitro*. This result suggests that some of the active components in *Achyranthes bidentata* could be used as inhibitors of TNF- $\alpha$  and IL-6.

The TP53-dependent apoptosis pathway is an essential mechanism of OA induced by chondrocyte apoptosis [42]. In osteoarthritis, TP53 can inhibit DNA replication, block cell cycle, lead

to apoptosis, and accelerate cartilage degradation [43]. TP53 is also a vital element of the protein interaction network. In this study, Western blot analysis confirmed that *Achyranthes bidentata* extract can inhibit the expression of p53 in rat degenerative chondrocytes *in vitro*, which indicates that some active components of *Achyranthes bidentata* are potential inhibitors of TP53.



**Figure 5.** Expression of proteins in chondrocytes exposed to IL-1β and/or *Achyranthes bidentata* extract (A–D). \* P<0.05 and \*\* P<0.01 vs. IL-1β-treated chondrocytes.

The results of GO and KEGG pathway analyses indicated that *Achyranthes bidentata* exerted its pharmacological effects in OA by modulating multiple pathways, including cell apoptosis, drug metabolism, inflammation, and immune modulation.

There are some limitations to this study. Systematic pharmacology is still in the early stage of development. At present, the data on drugs, compounds, proteins, and genes in the TCM database are incomplete, and the availability of the data obtained is limited [44]. In addition, there are differences between rat chondrocytes and human chondrocytes, and the present results need to be further verified in human chondrocytes and by *in vivo* experiments.

## Conclusions

In conclusion, *quercetin*, *baicalein*, and *berberine* are 3 important active components in the treatment of OA using *Achyranthes bidentata*. *Achyranthes bidentata* extract reduced the expression of TNF-α, IL-6, and p53 in degenerative chondrocytes. This study also showed that *Achyranthes bidentata* exerted its pharmacological effects in OA by modulating multiple pathways, including cell apoptosis, drug metabolism, inflammation, and immune modulation. However, this study is based on data mining analysis and *in vitro* experiments using rat chondrocytes, and our results need to be further verified in human chondrocytes and *in vivo* experiments.



## References:

1. Bijlsma JW, Berenbaum F, Lafeber FP: Osteoarthritis: An update with relevance for clinical practice. *Lancet*, 2011; 377(9783): 2115–26
2. Chahla J, Piuze NS, Mitchell JJ et al: Intra-articular cellular therapy for osteoarthritis and focal cartilage defects of the knee: A systematic review of the literature and study quality analysis. *J Bone Joint Surg Am*, 2016; 98(18): 1511–21
3. Taruc-Uy RL, Lynch SA: Diagnosis and treatment of osteoarthritis. *Prim Care*, 2013; 40(4): 821–36, vii
4. He X, Wang X, Fang J et al: The genus *Achyranthes*: A review on traditional uses, phytochemistry, and pharmacological activities. *J Ethnopharmacol*, 2017; 203: 260–78
5. Li J, Wang C, Han X et al: Transcriptome analysis to identify the putative biosynthesis and transport genes associated with the medicinal components of *achyranthes bidentata* Bl. *Front Plant Sci*, 2016; 7: 1860
6. Ma D, Li Y, Xiao W et al: *Achyranthes bidentata* extract protects chondrocytes functions through suppressing glycolysis and apoptosis via MAPK/AKT signaling axis. *Am J Transl Res*, 2020; 12(1): 142–52
7. Weng X, Lin P, Liu F et al: *Achyranthes bidentata* polysaccharides activate the Wnt/beta-catenin signaling pathway to promote chondrocyte proliferation. *Int J Mol Med*, 2014; 34(4): 1045–50
8. Hopkins AL: Network pharmacology: The next paradigm in drug discovery. *Nat Chem Biol*, 2008; 4(11): 682–90
9. Yue SJ, Xin LT, Fan YC et al: Herb pair Danggui-Honghua: Mechanisms underlying blood stasis syndrome by system pharmacology approach. *Sci Rep*, 2017; 7: 40318
10. Xiong Y, Yang Y, Xiong W et al: Network pharmacology-based research on the active component and mechanism of the antihepatoma effect of *Rubia cordifolia* L. *J Cell Biochem*, 2019; 120(8): 12461–72
11. Ma D, Yu T, Peng L et al: PIM1, CYP1B1, and HSPA2 targeted by quercetin play important roles in osteoarthritis treatment by *Achyranthes bidentata*. *Evid Based Complement Alternat Med*, 2019; 2019: 1205942
12. Ru J, Li P, Wang J et al: TCMSPP: A database of systems pharmacology for drug discovery from herbal medicines. *J Cheminform*, 2014; 6: 13
13. Cabrera-Pérez M, Pham-The H: Computational modeling of human oral bioavailability: What will be next? *Expert Opin Drug Discov*, 2018; 13(6): 509–21
14. Tao W, Xu X, Wang X et al: Network pharmacology-based prediction of the active ingredients and potential targets of Chinese herbal *Radix Curcumae* formula for application to cardiovascular disease. *J Ethnopharmacol*, 2013; 145(1): 1–10
15. Yue SJ, Liu J, Feng WW et al: System pharmacology-based dissection of the synergistic mechanism of Huangqi and Huanglian for diabetes mellitus. *Front Pharmacol*, 2017; 8: 694
16. Kuhn M, Szklarczyk D, Franceschini A et al: STITCH 3: Zooming in on protein-chemical interactions. *Nucleic Acids Res*, 2012; 40(Database issue): D876–80
17. Carvalho-Silva D, Pierleoni A, Pignatelli M et al: Open Targets Platform: New developments and updates two years on. *Nucleic Acids Res*, 2019; 47(D1): D1056–65
18. Kafkas Ş, Dunham I, McEntyre J: Literature evidence in open targets – a target validation platform. *J Biomed Semantics*, 2017; 8(1): 20
19. Shannon P, Markiel A, Ozier O et al: Cytoscape: A software environment for integrated models of biomolecular interaction networks. *Genome Res*, 2003; 13(11): 2498–504
20. von Mering C, Jensen LJ, Snel B et al: STRING: known and predicted protein-protein associations, integrated and transferred across organisms. *Nucleic Acids Res*, 2005; 33(Database issue): D433–37
21. Yu G, Wang LG, Han Y, He QY: clusterProfiler: An R package for comparing biological themes among gene clusters. *OMICS*, 2012; 16(5): 284–87
22. Huntley RP, Harris MA, Alam-Faruque Y et al: A method for increasing expressivity of Gene Ontology annotations using a compositional approach. *BMC Bioinformatics*, 2014; 15: 155
23. Ashburner M, Ball CA, Blake JA et al: Gene ontology: Tool for the unification of biology. *The Gene Ontology Consortium*. *Nat Genet*, 2000; 25(1): 25–29
24. Kanehisa M, Furumichi M, Tanabe M et al: KEGG: New perspectives on genomes, pathways, diseases and drugs. *Nucleic Acids Res*, 2017; 45(D1): D353–61
25. Science Mo, China TotPsRo. Guidance suggestions for the care and use of laboratory animals. Ministry of Science and Technology of P.R. China, 2006
26. Li X, Du M, Liu X et al: Millimeter wave treatment inhibits NO-induced apoptosis of chondrocytes through the p38MAPK pathway. *Int J Mol Med*, 2010; 25(3): 393–99
27. Li XH, Wu MX, Ye HZ et al: Experimental study on the suppression of sodium nitroprussiate-induced chondrocyte apoptosis by Tougu Xiaotong Capsule – containing serum. *Chin J Integr Med*, 2011; 17(6): 436–43
28. Sanchez C, Mathy-Hartert M, Deberg MA et al: Effects of rhein on human articular chondrocytes in alginate beads. *Biochem Pharmacol*, 2003; 65(3): 377–88
29. Wu SQ, Otero M, Unger FM et al: Anti-inflammatory activity of an ethnolic *Caesalpinia sappan* extract in human chondrocytes and macrophages. *J Ethnopharmacol*, 2011; 138(2): 364–72
30. Jiang Y, Zhang Y, Chen W et al: *Achyranthes bidentata* extract exerts osteoprotective effects on steroid-induced osteonecrosis of the femoral head in rats by regulating RANKL/RANK/OPG signaling. *J Transl Med*, 2014; 12: 334
31. Lin J, Wu G, Chen J et al: Electroacupuncture inhibits sodium nitroprussiate-mediated chondrocyte apoptosis through the mitochondrial pathway. *Mol Med Rep*, 2018; 18(6): 4922–30
32. Zheng YZ, Deng G, Liang Q et al: Antioxidant activity of quercetin and its glucosides from propolis: A theoretical study. *Sci Rep*, 2017; 7(1): 7543
33. Meng LQ, Yang FY, Wang MS et al: Quercetin protects against chronic prostatitis in rat model through NF-κB and MAPK signaling pathways. *Prostate*, 2018; 78(11): 790–800
34. Na JY, Song K, Kim S, Kwon J: Rutin protects rat articular chondrocytes against oxidative stress induced by hydrogen peroxide through SIRT1 activation. *Biochem Biophys Res Commun*, 2016; 473(4): 1301–8
35. Li L, Liu H, Shi W et al: Insights into the action mechanisms of Traditional Chinese Medicine in osteoarthritis. *Evid Based Complement Alternat Med*, 2017; 2017: 5190986
36. Ha TK, Hansen AH, Kol S et al: Baicalein reduces oxidative stress in CHO cell cultures and improves recombinant antibody productivity. *Biotechnol J*, 2018; 13(3): e1700425
37. Xing D, Gao H, Liu Z et al: Baicalin inhibits inflammatory responses to interleukin-1β stimulation in human chondrocytes. *J Interferon Cytokine Res*, 2017; 37(9): 398–405
38. Kumar A, Ekavali, Chopra K et al: Current knowledge and pharmacological profile of berberine: An update. *Eur J Pharmacol*, 2015; 761: 288–97
39. Li X, He P, Hou Y et al: Berberine inhibits the interleukin-1 beta-induced inflammatory response via MAPK downregulation in rat articular chondrocytes. *Drug Dev Res*, 2019; 80(5): 637–45
40. Hussein MR, Fathi NA, El-Din AM et al: Alterations of the CD4(+), CD8 (+) T cell subsets, interleukins-1beta, IL-10, IL-17, tumor necrosis factor-alpha and soluble intercellular adhesion molecule-1 in rheumatoid arthritis and osteoarthritis: Preliminary observations. *Pathol Oncol Res*, 2008; 14(3): 321–28
41. Björnsson GL, Thorsteinsson L, Gudmundsson KO et al: Inflammatory cytokines in relation to adrenal response following total hip replacement. *Scand J Immunol*, 2007; 65(1): 99–105
42. Li J, Lu D, Dou H et al: Publisher correction: Desumoylase SENP6 maintains osteochondrogenitor homeostasis by suppressing the p53 pathway. *Nat Commun*, 2018; 9(1): 646
43. Lin M, Lin Y, Li X et al: Warm sparse-dense wave inhibits cartilage degradation in papain-induced osteoarthritis through the mitogen-activated protein kinase signaling pathway. *Exp Ther Med*, 2017; 14(4): 3674–80
44. Zhou Z, Chen B, Chen S et al: Applications of network pharmacology in Traditional Chinese Medicine research. *Evid Based Complement Alternat Med*, 2020; 2020: 1646905